Widely adopted in diabetes, weight loss, chronic kidney disease and other chronic diseases, GLP‑1‑based peptides fuel rapid expansion of the global peptide drug market. Per Sullivan forecasts, the market will grow from $60.7 billion (2018) to $261.2 billion (2032). Patent expirations of major peptide drugs during 2014‑2026 boost generic development, pushing pharmaceutical companies to advance next‑generation peptide R&D and creating opportunities for upstream API and intermediate suppliers.

Though promising, the industry has high barriers to large‑scale R&D and production. Early‑stage peptide screening is difficult due to massive compound combinations, while long‑chain peptide libraries and mature target design methods remain insufficient. AI overcomes these challenges by simulating biomolecular structures to design complex long‑chain and cyclic peptides efficiently, reshaping peptide R&D patterns.

However, after peptide molecules are discovered, bottlenecks in synthesis and large‑scale production remain to be overcome. The growing number of structurally complex peptides brings challenges to traditional chemical synthesis, such as excessive impurities and difficult condensation. Traditional production lines with capacities of only 2,000–3,000 L cannot meet future ton‑scale demands. In the post‑GLP‑1 era, industrial competition centers on innovation in peptide synthesis and large‑scale manufacturing capabilities.

Technical Type	Chemical Synthesis	Traditional Biosynthesis	Innovative Biosynthesis
Peptide Length	< 30 amino acids	> 30 amino acids	Unlimited; obvious advantages even for peptides < 10 amino acids
R&D Investment	Medium	High	Medium
Production Cost	High	Medium	Low
Production Efficiency	Low	Medium	High

Currently, peptide synthesis is dominated by chemical methods, which suffer from complicated procedures, high costs, heavy environmental pressure, limited long‑peptide capacity and severe homogeneous competition domestically. Traditional biosynthesis also has drawbacks such as low expression yields and narrow applicability due to fundamental technical constraints, making it hard to replace chemical synthesis. Under such circumstances, synthetic biology emerges as a key solution with few domestic players and huge market potential.

Founded in 2020 with over a decade of synthetic biology expertise, Xiushi Biotech is China’s first firm to achieve large‑scale biosynthesis of complex short peptides. Building a multidisciplinary platform integrating AI, genetic engineering and fermentation technology, it has overcome technical bottlenecks including cyclization and unnatural amino‑acid modification. Its innovative biosynthesis technology, applied to over ten peptide products, cuts production costs to 10%‑20% of chemical synthesis and boosts efficiency more than fivefold. AI‑powered neural network models further accelerate R&D cycles.

Beyond technical breakthroughs, Xiushi Biotech has built a full‑chain layout. It runs a 5,000‑m² AI R&D center and a 13,000‑m² intelligent GMP manufacturing base, enabling flexible production from gram to ton scale for clinical and commercial supply. Serving clients in peptide drugs and cosmetic peptides, its smart production line is China’s first large‑scale GMP biosynthesis‑based peptide facility.

Going forward, competition in the peptide industry will shift from capacity expansion to technological innovation and ecosystem building. Xiushi Biotech will keep scaling up its intelligent production capacity, deepen cooperation with global pharmaceutical firms, strengthen industry‑university‑research collaboration, advance China’s peptide biosynthesis industrial upgrading, and fuel high‑quality development of the global peptide sector.

Changsha Luocheng Trading Co., Ltd. is a specialized supplier of high-purity peptides for the cosmetic, wellness, and fitness industries. Our core products include cosmetic peptides, anti-aging peptides, weight management peptides, and muscle-building peptides – serving skincare brands, supplement formulators, and health-focused companies worldwide.